Composition for improving skin sensitivity and enhancing pleasant mood and application thereof

By inhibiting TRPV1 receptors through a combination of Camellia chrysantha flower extract and other ingredients, this method addresses skin discomfort and anxiety associated with sensitive skin, achieving a dual improvement in skin comfort and emotional well-being. It is suitable for use in cosmetics to improve adverse reactions in sensitive skin.

CN118304233BActive Publication Date: 2024-11-08N O D TOPIA (GUANGZHOU) BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410407696.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-07
Publication Date
2024-11-08
Estimated Expiration
2044-04-07

AI Technical Summary

Technical Problem

In the current technology, people with sensitive skin face complex external factors that lead to increased skin sensitivity and decreased skin tolerance. Moreover, existing TRPV1 receptor channel inhibitors are not friendly and cannot effectively relieve skin discomfort and anxiety. There is a lack of safe and gentle ingredients that can meet the needs of both skin and mental well-being.

Method used

This product uses a combination of Camellia chrysantha flower extract, Cnidium monnieri extract, 4-tert-butylcyclohexanol, Rehmannia glutinosa extract, and metallothionein to synergistically inhibit TRPV1 receptors, reduce cortisol secretion, alleviate skin sensitivity, and enhance feelings of pleasure.

Benefits of technology

It effectively relieves symptoms such as burning, itching, and stinging in sensitive skin, improves skin comfort and pleasure, enhances the skin barrier, promotes positive emotions, and achieves dual improvement in both skin and mind.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118304233B_ABST
    Figure CN118304233B_ABST
Patent Text Reader

Abstract

The present invention discloses a composition and its application for improving skin sensitivity and promoting pleasant emotions, belonging to the field of cosmetic technology; The composition provided by the present invention includes the following components in parts by weight: 0.5-10 parts of golden camellia extract, 0.1-8 parts of cnidium monnieri extract, 0.01-2 parts of 4-tert-butyl cyclohexanol, 0.005-1 parts of metallothionein, and 0.03-3 parts of Rehmannia glutinosa extract. The composition provided by the present invention can effectively inhibit TRPV1 receptors, reduce the damage of cortisol to sensitive skin, so as to relieve the sensitive state of sensitive skin, reduce the discomfort such as itching, stinging, and burning, improve the skin reactions such as dryness, erythema, and stinging, and can significantly improve the positive and pleasant emotions of sensitive skin crowds, and comprehensively improve the comfort of sensitive skin from three aspects of skin perception, skin state, and sensitive skin crowd emotions, and can achieve excellent relieving sensitive effects. Moreover, the composition provided by the present invention improves skin sensitivity, promotes pleasant emotions, and the component sources of its application are natural, and the preparation method is simple, which is suitable for actual production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of cosmetics, and in particular relates to a composition for improving skin sensitivity and enhancing pleasant mood and an application thereof. Background Art

[0002] Sensitive skin refers to a highly reactive state of the skin under physiological or pathological conditions, mainly occurring on the face. Clinically, the skin is prone to subjective symptoms such as burning, itching and pain when stimulated by external factors. Studies have shown that the symptoms of sensitive skin are closely related to nerve targets. Transient receptor potential channels (TRP) are a group of ion channels located on the plasma membranes of various cells. The activation of TRPV1 channels is a key trigger for skin discomfort.

[0003] However, with the development of science and technology and economy, the external factors faced by sensitive skin are becoming more and more complex, which will lead to increased skin sensitivity, long-lasting sensitivity, and a sharp decrease in skin tolerance, which makes it more challenging for people with sensitive skin to solve skin problems. As a result, people with sensitive skin will have a lot of anxiety in their daily lives, and this negative emotion will increase the sensitivity of the skin, and jointly affect skin health with skin discomfort reactions. Cortisol is a stress hormone. There are a large number of glucocorticoid receptors on the surface of skin cells. When the pressure of external factors or psychological pressure (anxiety) will promote the secretion of cortisol, it will cause skin sensitivity reactions, such as dryness and erythema. Affect the physical and mental health and quality of life of people with sensitive skin, especially those with moderate and severe sensitive skin. Therefore, sensitive skin is not just a skin problem. The anxiety of people with sensitive skin in daily life is also ubiquitous. It cannot achieve a positive state of relief and comfort under external stimulation at both the skin and mental levels, that is, it cannot achieve a state of skin comfort.

[0004] However, on the one hand, although the prior art provides a variety of TRPV1 receptor channel inhibitors that can reduce skin discomfort, most of the TRPV1 receptor channel inhibitors are not friendly to people with sensitive skin, lack clinical trials, and highly specific inhibitors are not commercially available and are not very practical. On the other hand, the prior art ignores the impact of emotions on the skin and the importance of coordination between skin perception and spirit. Sensitive skin is in a state of damaged barrier for a long time and is constantly threatened by various external factors. Therefore, there is an urgent need to develop safe and gentle ingredients or products that can reduce the discomfort of sensitive skin and help people with sensitive skin to obtain good skin comfort in complex environments to meet the needs of sensitive skin consumers. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies of the above-mentioned prior art and provide a composition and its application for improving skin sensitivity and enhancing pleasant mood, which can effectively improve the discomfort reaction of sensitive skin, relieve symptoms such as burning, stinging, itching, redness, etc., and enhance the user's pleasant feeling.

[0006] To achieve the above objectives, in a first aspect of the present invention, the present invention provides a composition for improving skin sensitivity and enhancing pleasant mood, the composition comprising the following components in parts by weight:

[0007] 0.5-10 parts of Camellia chrysantha extract, 0.1-8 parts of Cnidium monnieri extract, 0.01-2 parts of 4-tert-butyl cyclohexanol, 0.005-1 parts of metallothionein, and 0.03-3 parts of Rehmannia glutinosa extract.

[0008] The composition for improving skin sensitivity and enhancing pleasant mood provided by the present invention selects appropriate weight portions of Camellia chrysantha extract, Cnidium monnieri extract, 4-tert-butyl cyclohexanol, Rehmannia glutinosa extract and metallothionein. The five components can cooperate with each other to effectively inhibit TRPV1 receptors and inhibit skin damage caused by excessive secretion of "stress factor" cortisol, thereby soothing the sensitive state of sensitive skin, reducing dryness, erythema, itching, tingling, etc., and further improving the comfort of sensitive skin, achieving an excellent effect of alleviating sensitivity.

[0009] Specifically, golden camellia is a flower of the Camellia genus of the Theaceae family. It can be used for food and medicine. It is very precious. The tea brewed with golden camellia is not only golden in color, but also rich in nutrition, beneficial to health, and has the effects of clearing heat and quenching thirst, moistening the lungs and relieving cough, and regulating blood lipids. Cnidium monnieri was first included in the "Shennong Bencao Jing" and has been used in medical practice for thousands of years. It is also known as wild fennel and wild coriander. It is the dried mature fruit of the Umbelliferae plant Cnidium monnieri. It has a strong aromatic aroma. Its nature and flavor are pungent, bitter, and warm. It has the effects of warming the kidney and strengthening yang, killing insects and relieving itching. 4-tert-butyl cyclohexanol is a TRPV1 antagonist that can have a good alleviating effect on the stimulation response induced by TRPV1 activation. Rehmannia glutinosa belongs to the Scrophulariaceae family. It can clear heat and cool blood, nourish yin and promote fluid production. The main components include glycosides, oligosaccharides, amino acids, etc., which have the effects of lowering blood sugar, anti-aging, and anti-tumor. Metallothionein is a low molecular weight, cysteine-rich metal binding protein that participates in maintaining the homeostasis of copper and zinc metals and mediates the function of heavy metal detoxification by scavenging free radicals to combat oxidative stress. The present invention uses the above five compositions in combination to synergistically alleviate various discomfort perceptions and negative emotions of people with sensitive skin, achieve an efficient soothing effect on the skin, and provide a high-quality sense of comfort for sensitive skin.

[0010] As a preferred embodiment of the composition of the present invention, the composition comprises the following components in parts by weight: 0.8-5 parts of Camellia chrysantha extract, 1-5 parts of Cnidium monnieri extract, 0.1-1.5 parts of 4-tert-butyl cyclohexanol, 0.008-0.1 parts of metallothionein, and 0.05-0.5 parts of Rehmannia glutinosa extract.

[0011] As a preferred embodiment of the composition of the present invention, the composition comprises the following components in parts by weight: 1 part of Camellia chrysantha extract, 3 parts of Cnidium monnieri extract, 1 part of 4-tert-butyl cyclohexanol, 0.01 parts of metallothionein, and 0.1 parts of Rehmannia glutinosa extract.

[0012] The present invention has been found that the weight of the components in the composition for improving skin sensitivity and enhancing pleasant mood will affect the performance of the product. When the mass of the components is further selected to be within the above range, the obtained product has a stronger inhibitory effect on the TRPV1 channel and can more effectively reduce the damage of the stress substance cortisol to the skin, thereby having a better effect of alleviating the apparent symptoms of sensitive skin and improving skin comfort.

[0013] As a preferred embodiment of the composition of the present invention, the mass ratio of the Rehmannia glutinosa extract, 4-tert-butyl cyclohexanol and Camellia chrysantha extract is 1:(3-12):(6-20).

[0014] The present invention has found that the mass ratio of the Rehmannia root extract, 4-tert-butyl cyclohexanol and Camellia chrysantha extract in the composition will also affect the comprehensive performance of the product to a certain extent. When the mass ratio of the Rehmannia root extract, 4-tert-butyl cyclohexanol and Camellia chrysantha extract is further selected to be 1:(3-12):(6-20), the product has a stronger inhibitory ability on the TRPV1 receptor and can significantly improve the damage to the skin caused by elevated cortisol in sensitive skin, thereby achieving a more excellent effect in alleviating sensitive symptoms.

[0015] As a preferred embodiment of the composition of the present invention, the preparation method of the Camellia chrysantha extract comprises the following steps: extracting Camellia chrysantha powder by mixing with ethanol aqueous solution, and then concentrating the extract and drying it to obtain the Camellia chrysantha extract.

[0016] The present invention has found that when the golden camellia powder is mixed with an ethanol aqueous solution for extraction, the golden camellia extract can be well matched with other components to achieve excellent effects of soothing sensitivity and improving the comfort of sensitive skin. Specifically, the mixed extraction method can be at least one of immersion, ultrasonic extraction, and reflux extraction.

[0017] As a preferred embodiment of the composition of the present invention, the preparation method of the Camellia chrysantha extract comprises the following steps: mixing Camellia chrysantha powder with ethanol aqueous solution, then extracting at 55-65°C for 25-35 minutes, then ultrasonically extracting at 55-65°C for 55-65 minutes, then concentrating the extract and drying to obtain Camellia chrysantha extract.

[0018] In the ethanol aqueous solution, the volume percentage of ethanol is 60-80%; the weight ratio of the golden camellia powder to the ethanol aqueous solution is 1:(5-10).

[0019] Preferably, the ultrasonic power is 280-300W.

[0020] Preferably, the preparation method of the Camellia chrysantha powder is: collect Camellia chrysantha flowers, wash them, put them into a constant temperature oven at 60-70°C and dry them to constant weight, then grind and crush them and pass them through a 100-150 mesh sieve, collect the sieved material to obtain Camellia chrysantha powder.

[0021] Preferably, the temperature of the concentrated extract is 45-55°C.

[0022] As a preferred embodiment of the composition of the present invention, the preparation method of the Cnidium monnieri extract comprises the following steps: extracting Cnidium monnieri powder by mixing with ethanol aqueous solution, followed by concentration, decolorization and drying to obtain the Cnidium monnieri extract.

[0023] The present invention has found that when the Cnidium monnieri powder is mixed with an ethanol aqueous solution for extraction, the Cnidium monnieri extract can be well matched with other components, thereby better inhibiting TRPV1 receptors and enhancing the resistance of sensitive skin to the stress factor cortisol, thereby achieving a better effect of relieving sensitive symptoms. Specifically, the mixed extraction method can be at least one of ultrasonic extraction and reflux extraction.

[0024] As a preferred embodiment of the composition of the present invention, the preparation method of the Cnidium monnieri extract comprises the following steps: taking Cnidium monnieri powder and mixing it with an ethanol aqueous solution added with a surfactant, refluxing and ultrasonically extracting it, and then concentrating, decolorizing and drying it to obtain the Cnidium monnieri extract.

[0025] The present invention has found that when a surfactant is further added during the extraction process, the relevant active substances can be extracted more effectively. When the Cnidium monnieri extract prepared by the preparation method is applied to the composition of the present invention, the synergistic effect between the components is stronger and the comprehensive performance of the obtained product is better.

[0026] As a preferred embodiment of the composition of the present invention, at least one of the following (a)-(e):

[0027] (a) the volume percentage of ethanol in the ethanol aqueous solution is 70-95%;

[0028] (b) the weight ratio of the Cnidium monnieri powder to the ethanol aqueous solution is 1:(1-5);

[0029] (c) based on the mass of the Cnidium monnieri powder, the amount of surfactant added is 0.01-0.4%;

[0030] (d) the surfactant comprises at least one of Tween 20, Tween 60, Tween 80 and sodium lauryl sulfate;

[0031] (e) The power of the ultrasound is 250-280W.

[0032] Preferably, the decolorization is performed by adding activated carbon; the amount of activated carbon added is 1-5% of the mass of the concentrated liquid.

[0033] Preferably, the mesh size of the Cnidium monnieri powder is 100-150 meshes.

[0034] As a preferred embodiment of the composition of the present invention, the preparation method of the Rehmannia root extract comprises the following steps: taking Rehmannia root powder and subjecting it to supercritical carbon dioxide extraction, followed by filtering and concentrating the extract to obtain the Rehmannia root extract.

[0035] The present invention has found that the extraction rate of the effective ingredients obtained by using supercritical carbon dioxide is higher, thereby achieving a better comprehensive effect of the composition.

[0036] Preferably, in the carbon dioxide supercritical extraction, the extraction temperature is 45-55° C., the extraction pressure is 35-45 MPa, the entrainer (80-90% ethanol) flow rate is 1-2 mL / min, and the extraction time is 110-130 min.

[0037] Preferably, the filtration is performed using absorbent cotton.

[0038] In a second aspect of the present invention, the present invention provides a method for preparing the composition for improving skin sensitivity and enhancing pleasant mood, the preparation method comprising the following steps:

[0039] (1) uniformly mixing the Camellia chrysantha extract, the Cnidium monnieri extract, 4-tert-butyl cyclohexanol and the Rehmannia glutinosa extract to obtain a composition 1;

[0040] (2) dissolving metallothionein in deionized water to form a 1% by mass metallothionein aqueous solution to obtain composition 2;

[0041] (3) The composition 1 and the composition 2 are mixed evenly to obtain a composition for improving skin sensitivity and enhancing pleasant mood.

[0042] In the third aspect of the present invention, the present invention provides a use of the composition in preparing cosmetics.

[0043] The present invention has been found in research that the composition provided by the present invention can be added into different cosmetics as an effective ingredient, thereby achieving the effect that the cosmetics effectively improve the discomfort reaction of sensitive skin, relieve symptoms such as burning, stinging, itching, redness, etc., and enhance the user's pleasant feeling.

[0044] In a fourth aspect of the present invention, the present invention provides a cosmetic comprising the composition of the present invention.

[0045] As a preferred embodiment of the cosmetics of the present invention, the cosmetics include the following components in percentage by mass: 1-5% of the composition of the present invention, 4-40% of the cosmetic base, and the balance of water.

[0046] As a preferred embodiment of the cosmetics of the present invention, the cosmetic matrix includes at least one of a thickener, a moisturizer, an emulsifier, a preservative, and a pH adjuster.

[0047] As a preferred embodiment of the cosmetics of the present invention, the cosmetics include the following components in mass percentage: 1-5% of the composition of the present invention, 0.05-0.5% of a thickener, 3-20% of a moisturizer, 0.5-10% of an emulsifier, 0.2-5% of a preservative, 0.05-0.1% of a pH adjuster, and the balance is water.

[0048] Exemplarily, the thickener includes at least one of xanthan gum, carbomer 940, AVC, and high molecular weight cellulose; the humectant includes at least one of glycerin, butylene glycol, and low molecular weight sodium hyaluronate; the emulsifier includes at least one of coconut oil alcohol-caprylate / caprate, polydimethylsiloxane, hydrogenated palm kernel oil, cetearyl alcohol, polyglyceryl-6 distearate, and polymethylsilsesquioxane; the preservative includes at least one of 1,3-propylene glycol, 1,2-hexanediol, and parahydroxyacetophenone; the pH adjuster includes at least one of arginine and EDTA-2Na.

[0049] As a preferred embodiment of the cosmetics of the present invention, the cosmetics include any one of lotion, emulsion, paste, cream, mask, essence, spray and gel.

[0050] In a fifth aspect of the present invention, the present invention provides a method for preparing a cosmetic, the preparation method comprising the following steps:

[0051] (1) Mixing a humectant, a thickener and part of a pH adjuster with water, stirring, heating to 80-90° C., homogenizing at a speed of 1000-1400 rpm for 3-5 minutes, and keeping warm for later use after homogenization to obtain a prefabricated component A;

[0052] (2) Mix the emulsifier, heat to 70-80° C., homogenize at 1000-1400 rpm for 3-5 min, and keep warm for later use to obtain prefabricated component B;

[0053] (3) Mix the preservatives and heat to 55-65° C. to melt to obtain a prefabricated C component;

[0054] (4) The preformed component A is heated to 75-85°C, and the preformed component B is added at a speed of 200-500 rpm, and stirred and mixed. Then, the temperature is lowered to 55-65°C, and the preformed component C is added at a speed of 200-500 rpm, and stirred and mixed. Then, the temperature is lowered to below 45°C, and the composition of the present invention is added and stirred for 5-10 minutes. Finally, the remaining pH adjuster is added to adjust the pH to 5.0-6.5, and the stirring is stopped. The material is discharged to obtain the cosmetic.

[0055] Compared with the prior art, the present invention has the following beneficial effects:

[0056] (1) The present invention provides a composition for improving skin sensitivity and enhancing pleasant mood. The composition selects appropriate weight portions of Camellia chrysantha extract, Cnidium monnieri extract, 4-tert-butyl cyclohexanol, Rehmannia glutinosa extract and metallothionein. The five components can work together to effectively inhibit TRPV1 receptors and reduce the cortisol content in sensitive skin. The composition can comprehensively focus on the skin and psychological problems of patients with sensitive skin, effectively alleviate various skin discomforts such as burning, itching and pain caused by external stimuli, and positively regulate skin reactions. The effect of the present invention is not only superficial, but also helps to improve the inner anxiety of patients with sensitive skin, effectively resist external stressors, promote users' soothing, pleasant and safe feelings, mobilize positive emotions, positively regulate psychology, and take both internal and external factors into consideration, which is beneficial to promoting the improvement of the comfort of sensitive skin.

[0057] (2) The composition provided by the present invention not only improves the uncomfortable skin perception and anxiety of patients with sensitive skin, but also has a significant improvement effect on the skin condition, so that the sensitive skin barrier is improved, the skin texture is delicate, smooth and moisturized, and then a virtuous cycle effect is generated, achieving a long-term and stable skin care effect;

[0058] (3) The composition provided by the present invention is combined with cell models, 3D skin models, and human trials, and multi-dimensional validation of efficacy shows that it can achieve the effects of rapid soothing, prevention of sensitivity, and long-term stabilization. It has high credibility, obvious effects, simple operation, and no restrictions on the applicable population. It can be widely used in the prevention and management of sensitive skin reactions and the promotion of positive emotions in people with sensitive skin. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 This is the result of TRPV1 immunofluorescence in effect example 1;

[0060] Figure 2 This is the result of zebrafish tail fin skin restoration in effect example 2;

[0061] Figure 3 This is the result diagram of the changes in the facial red area before and after using Application Example 1 in Effect Example 3. DETAILED DESCRIPTION

[0062] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0063] Unless otherwise specified, the reagents, methods and equipment used in the present invention are all conventional reagents, methods and equipment in the art; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch of raw materials.

[0064] Camellia chrysantha extract 1: homemade, the preparation method is as follows: collect Camellia chrysantha flowers, wash and put them into a 65°C constant temperature oven to dry to constant weight, grind and crush them, pass them through a 100-mesh sieve, collect the sieved material to obtain Camellia chrysantha powder; add 8 times the volume fraction of 70% ethanol aqueous solution to the Camellia chrysantha powder, and extract at 60°C for 30 minutes; then extract at an ultrasonic power of 290W and a temperature of 60°C for 1 hour; filter after the extraction, collect the extract, and concentrate the extract by rotary evaporation at 50°C. After the concentration, place it in an ultra-low temperature freeze dryer for drying and freezing to obtain Camellia chrysantha extract 1;

[0065] Camellia chrysantha extract 2: homemade, the preparation method is as follows: collect Camellia chrysantha flowers, wash and put them into a 65°C constant temperature oven to dry to constant weight, grind and crush them, pass them through a 150-mesh sieve, collect the sieved material to obtain Camellia chrysantha powder; add 20 times the volume fraction of 55% ethanol aqueous solution to the Camellia chrysantha powder, extract for 1 hour at an ultrasonic power of 300W and a temperature of 35°C; filter after the extraction, collect the extract, and concentrate the extract by rotary evaporation at 50°C. After the concentration, place it in an ultra-low temperature freeze dryer for drying and freezing to obtain Camellia chrysantha extract 2;

[0066] Camellia chrysantha extract 3: homemade, the preparation method is as follows: collect Camellia chrysantha flowers, wash and put them into a 50°C constant temperature oven to dry to constant weight, grind and crush them, pass them through a 100-mesh sieve, collect the sieved material to obtain Camellia chrysantha powder; add 15 times the volume fraction of 70% ethanol aqueous solution to the Camellia chrysantha powder, and then reflux extract at 80°C for 1.5h; filter after the extraction, collect the extract, and concentrate the extract by rotary evaporation at 50°C. After the concentration, place it in an ultra-low temperature freeze dryer to dry and freeze, and obtain Camellia chrysantha extract 3;

[0067] Cnidium monnieri extract 1: homemade, the preparation method is as follows: crush Cnidium monnieri, add 3 times the volume fraction of 95% ethanol aqueous solution, then add surfactant Tween 80 (38 mg surfactant is added for every 50 g Cnidium monnieri), then reflux extract for 2 hours at 260W ultrasonic power, and repeat the extraction of the residue twice; combine the extracts, concentrate under reduced pressure, add 1.25% by mass activated carbon to the concentrated solution for decolorization, filter after decolorization, collect the filtrate and vacuum dry it at 70°C to constant weight to obtain Cnidium monnieri extract 1;

[0068] Cnidium monnieri extract 2: homemade, the preparation method is as follows: crush Cnidium monnieri and add 3 times the volume fraction of 75% ethanol aqueous solution, then add surfactant Tween 80 (38 mg surfactant is added for every 50 g Cnidium monnieri), then reflux extract for 1 h at 360 W ultrasonic power, and extract the residue twice; combine the extracts, concentrate under reduced pressure, and then vacuum dry at 70° C. to constant weight to obtain Cnidium monnieri extract 2;

[0069] Cnidium monnieri extract 3: homemade, the preparation method is as follows: crush Cnidium monnieri, add 6 times the volume fraction of 75% ethanol aqueous solution, reflux extraction at 100°C for 1.5h, and extract the residue twice; combine the extracts, concentrate under reduced pressure and dry them to obtain Cnidium monnieri extract 3;

[0070] Rehmannia root extract 1: Put Rehmannia root powder into a supercritical extraction kettle, the entrainer is 85% alcohol by volume, the entrainer flow rate is 2mL / min, turn on the water bath switch, and pass CO 2 , set the temperature to 50℃, when the extraction device reaches the set temperature, turn on the CO 2 The pump was adjusted to a set pressure of 40 MPa, and after 2 hours of extraction, the extract was collected, and the extraction was repeated 3 times. The collected extract was filtered with absorbent cotton, and the filtrate was concentrated under reduced pressure to remove water and ethanol to obtain Rehmannia glutinosa extract 1, which was stored in a refrigerator at room temperature;

[0071] Rehmannia root extract 2: After crushing Rehmannia root, pass through 60 mesh, add 10 times distilled water, decoct twice, each decoction time is 1 hour, combine the filtrate, filter, and extract by ultrasonic twice, each time for 1.5 hours, to obtain Rehmannia root extract 2;

[0072] Metallothionein: Commercially available.

[0073] Examples 1-11 and Comparative Examples 1-5

[0074] Examples 1-11 of the present invention and comparative examples 1-5 provide a composition for improving skin sensitivity and enhancing pleasant mood, and the components (parts by mass) of the composition are shown in Table 1;

[0075] Table 1

[0076]

[0077]

[0078] The preparation method of the composition for improving skin sensitivity and enhancing pleasant mood provided in Example 1 is:

[0079] (1) uniformly mixing the Camellia chrysantha extract, the Cnidium monnieri extract, 4-tert-butyl cyclohexanol and the Rehmannia glutinosa extract to obtain a composition 1;

[0080] (2) dissolving metallothionein in deionized water to form a 1% by mass metallothionein aqueous solution to obtain composition 2;

[0081] (3) The composition 1 and the composition 2 are mixed evenly to obtain a composition for improving skin sensitivity and enhancing pleasant mood.

[0082] Comparative Example 6

[0083] The comparative example of the present invention provides a composition for improving skin sensitivity and enhancing pleasant mood. The only difference between the composition and Example 1 is that the honeysuckle extract is used to replace the golden camellia extract 1.

[0084] Comparative Example 7

[0085] The comparative example of the present invention provides a composition for improving skin sensitivity and enhancing pleasant mood. The only difference between the composition and Example 1 is that the Cnidium monnieri extract is replaced with Sophora flavescens extract.

[0086] Comparative Example 8

[0087] The comparative example of the present invention provides a composition for improving skin sensitivity and enhancing pleasant mood. The only difference between the composition and Example 1 is that the Rehmannia root extract is replaced by the liquorice extract.

[0088] Comparative Example 9

[0089] The comparative example of the present invention provides a composition for improving skin sensitivity and enhancing pleasant mood. The only difference between the composition and Example 1 is that phytochelatin is used to replace metallothionein.

[0090] Application examples 1-12, comparative application examples 1-10 and blank application examples

[0091] Application Examples 1-12, Comparative Application Examples 1-10 and Blank Application Examples of the present invention provide an emulsion, the components (mass percentage) of the emulsion are shown in Table 2; wherein the compositions for improving skin sensitivity and enhancing pleasant emotions in Application Examples 1-11 are respectively the compositions for improving skin sensitivity and enhancing pleasant emotions prepared in Examples 1-11, and the compositions for improving skin sensitivity and enhancing pleasant emotions in Comparative Application Examples 1-9 are respectively the compositions for improving skin sensitivity and enhancing pleasant emotions prepared in Comparative Examples 1-9; for example, the composition for improving skin sensitivity and enhancing pleasant emotions used in Application Example 6 is the composition for improving skin sensitivity and enhancing pleasant emotions prepared in Example 6, and the same can be said for the others; the composition for improving skin sensitivity and enhancing pleasant emotions used in Application Example 12 is the composition for improving skin sensitivity and enhancing pleasant emotions prepared in Example 1;

[0092] Table 2

[0093]

[0094]

[0095] The preparation method of the emulsion provided in Application Example 1 is:

[0096] (1) Component A and water are mixed and stirred, heated to 80° C., homogenized at a speed of 1200 rpm for 5 minutes, and kept warm for later use to obtain prefabricated component A;

[0097] (2) Mixing component B, heating to 80° C., homogenizing at 1200 rpm for 5 min, and keeping warm for later use to obtain prefabricated component B;

[0098] (3) mixing the C components and heating them to 60° C. to melt them to obtain a prefabricated C component;

[0099] (4) The preformed component A is heated to 80°C, and the preformed component B is added at a speed of 300 rpm, and the mixture is stirred and mixed. Then, the temperature is lowered to 60°C, and the preformed component C is added at a speed of 300 rpm, and the mixture is stirred and mixed. Then, the temperature is lowered to below 45°C, and the composition for improving skin sensitivity and enhancing pleasant mood is added, and stirring is continued for 5 minutes. Finally, arginine is added to adjust the pH to 5.0-6.5, and stirring is stopped. The material is discharged to obtain an emulsion.

[0100] The preparation methods of the emulsions provided in Application Examples 2-12, Comparative Application Examples 1-10 and Blank Application Examples are consistent with that in Application Example 1, and no relevant components are added.

[0101] Effect Example 1

[0102] The effect examples of the present invention verify the inhibitory effect of the compositions for improving skin sensitivity and enhancing pleasant mood prepared in Examples 1-11 and Comparative Examples 1-9 on TRPV1 expression, which specifically include the following contents:

[0103] (1) Grouping information: divided into a sample group (the compositions in Examples 1-11 and Comparative Examples 1-9), a positive control group (PC, novanillin), a negative control group (NC), and a blank control group (BC);

[0104] (2) Process: Epidermal Skin Model The samples were transferred to the well plate, and EpiGrowth culture medium was added in advance. The test group number was marked on the well plate. Three parallels were set for each group. The BC group was not treated. The NC group, PC group and sample group were added with EpiGrowth culture medium containing 15 μM capsaicin CAP. The PC group and sample group were added with sample working solution of corresponding concentration (the concentration of the PC group was 15.6 μg / mL, and the volume concentration of the sample working solution group was 0.015% of the culture solution). The samples were evenly distributed on the surface of the model and placed in CO 2 Incubator (37°C, 5% CO 2 ) and incubate for 24 h; after the incubation, clean the test substance remaining on the surface of the model with sterile PBS solution, and wipe the residual liquid inside and outside the model with a sterile cotton swab;

[0105] (3) TRPV1 detection: Fix the cells with 4% paraformaldehyde for 30 min, perform immunofluorescence detection of capsaicin receptor TRPV1, observe under a microscope, collect images for analysis and record the optical density (IOD);

[0106] (4) Statistical analysis of results: The results were expressed as Mean ± SD. The t-test was used for comparison between the groups. P < 0.05 was considered to be a significant difference, and P < 0.01 was considered to be a very significant difference.

[0107] The results obtained are shown in Table 3, where the inhibition rate is calculated as follows: inhibition rate = (average relative IOD value of negative control group - average relative IOD value of sample group) / average relative IOD value of negative control group × 100%;

[0108] The relative IOD refers to the accumulated optical density in each reaction well at each measurement, which is a relative value without unit; the relative IOD average refers to the average relative IOD value obtained from each measurement of three parallel reaction wells.

[0109] Table 3

[0110]

[0111] Note: When using t-test method for statistical analysis, the significance is # indicates that P-value<0.05 indicates that # , P-value<0.01 is indicated as ## Compared with the NC group, the * indicates that P-value<0.05 indicates that * , P-value<0.01 is indicated as ** , P-value>0.05 is indicated as ns ;

[0112] As can be seen from Table 3, based on the 3D epidermal skin model, the expression of TRPV1 protein was tested by immunofluorescence. Compared with the blank group, the TRPV1 protein content in the negative control group increased significantly, indicating that the stimulation conditions were effective. Compared with the negative control group, the TRPV1 protein content in the positive control group decreased significantly, indicating that the positive control in this test was effective. Compared with the negative control group, when the technical scheme of the present invention was adopted, the obtained Examples 1-11 significantly decreased the TRPV1 protein content at a concentration of 0.015%, and the inhibition rate was in the range of 73.90-42.64%, among which Example 1 had the best inhibition effect and had a very significant effect. In addition, the experiment was conducted using the active ingredient purslane extract, which is known to have a soothing effect, and it was found that the effect of Example 1 was 4.47 times higher than that of the purslane extract. Therefore, it is shown that the technical scheme of the present invention can improve the discomfort of skin nerve sensation by inhibiting the expression of TRPV1 protein;

[0113] When any one of the components in the composition is missing in Comparative Examples 1-5, almost no inhibitory effect is shown, and no soothing effect is achieved; when other similar components are used to replace the components in the present invention in Comparative Examples 6-9, the inhibitory effect on TRPV1 cannot be achieved;

[0114] In addition, the results of fluorescence photography during the detection process are recorded as follows: Figure 1 As shown, from Figure 1 It can also be intuitively seen that, compared with the negative control group and the purslane extract, the composition in Example 1 of the present invention can effectively reduce the TRPV1 protein content, and the result is even better than the positive control group, that is, the composition provided by the present invention has an excellent effect of inhibiting TRPV1 channels.

[0115] Effect Example 2

[0116] Effect Example of the Present Invention The compositions for improving skin sensitivity and enhancing pleasant mood prepared in Examples 1-11 and Comparative Examples 1-9 were evaluated for improvement of skin damage induced by stress hormones, specifically including the following contents:

[0117] Long-term stress can cause multiple types of damage to the skin, such as decreased immunity, inflammation, reduced energy, and slower detoxification, which reduces the ability to resist external stressors, slows the recovery of skin wounds, and increases skin sensitivity. When zebrafish's skin is injured, once it has passed the embryonic stage, wound healing becomes slow and requires steps such as coagulation, inflammation, skin regeneration, blood vessel regeneration, and the formation of granulation tissue. In the process of wound repair, zebrafish, except for the inability to coagulate, the rest of the steps are the same as humans, and can be used as a test model for the efficacy of human skin repair. This effect example uses the stressor cortisol to delay the healing process of zebrafish skin, establishes a cortisol skin damage model, and evaluates the effect of the sample on resisting cortisol skin damage. The experimental steps are:

[0118] (1) Zebrafish farming: Use wild-type AB strain zebrafish (Danio rerio) from a reliable source (such as the China National Zebrafish Resource Center) for testing. The water temperature should be controlled at 26-28°C, and the indoor temperature is recommended to be controlled at 20-25°C;

[0119] (2) Preparation of test substance: Dimethyl sulfoxide was mixed with the test substance at a ratio of 1:1, ultrasonicated for 10 min, and then added to the fish embryo culture medium to prepare the required concentration. After shaking for 30 s, centrifuged at 6500×g for 10 min. The supernatant was taken for testing. The concentration of the test solution of the test substance must ensure that the mortality rate of zebrafish is ≤10% (embryos without heartbeat characteristics are defined as dead);

[0120] (3) Preparation of other solutions: Cortisol solution was prepared by weighing cortisol powder and dissolving it in water to prepare a 5 mg / L stock solution. The working solution was prepared by diluting the stock solution 100 times with fish embryo culture medium. Tricaine solution was prepared by weighing 200 mg of tricaine and dissolving it in 48.95 mL of water and refrigerating. Fish embryo culture medium (prepared by weighing 2940 mg of anhydrous calcium chloride, 1233 mg of magnesium sulfate heptahydrate, 630 mg of sodium bicarbonate, and 55 mg of potassium chloride and dissolving them in 10 L of water, pH 6.5-8.5)

[0121] (4) Fin removal step: Use tricaine solution to anesthetize the zebrafish embryo, and remove the tail fin of the zebrafish embryo with a laboratory scalpel under a microscope;

[0122] (5) Test grouping: The test needs to set up a blank control group (fish embryo culture medium), a model control group (cortisol solution) and a test group (test substance + cortisol solution). The blank control group was set up as 24 fish embryos randomly selected, the fins were removed and transferred to a 96-well plate, each well containing one fish embryo and 0.2mL fish embryo culture medium; the model control group was set up as 24 fish embryos randomly selected, the fins were removed and transferred to a 96-well plate, each well containing one fish embryo and 0.2mL cortisol solution; the test group was set up as 24 fish embryos randomly selected, the fins were removed and transferred to a 96-well plate, each well containing one fish embryo and 0.2mL test substance solution (5mg / L) + cortisol solution; placed in a constant temperature of 28±1℃ and cultured for 3±0.5h;

[0123] (6) Sample microscopic analysis: The zebrafish was anesthetized with tricaine and then placed under a stereomicroscope to take side-on photos of the tail of the fish embryo, and the length changes were analyzed pixel by pixel;

[0124] (7) Data and result calculation: Count the length of the caudal fin of each fish embryo on the 7th day (pixels). Calculate the promotion rate of caudal fin repair: Promotion rate = (BA) / (CA)×100%,

[0125] Among them, A: the average tail fin length of fish embryos in the blank control group;

[0126] B: The average tail fin length of fish embryos in the model control group;

[0127] C: Average tail fin length of fish embryos in the sample group

[0128] A two-tailed T test was performed on the caudal fin length of the fish embryos treated with the test substance and the caudal fin length of the model control group to obtain the P value;

[0129] The test results are shown in Table 4;

[0130] Table 4

[0131] Group Promotion rate / % Group Promotion rate / % Example 1 <![CDATA[115.23 *** ]]> Comparative Example 1 <![CDATA[-7.13 ns ]]> Example 2 <![CDATA[88.24 ** ]]> Comparative Example 2 <![CDATA[-3.58 ns <!-- 11 -->]]> Example 3 <![CDATA[78.23 ** ]]> Comparative Example 3 <![CDATA[-4.14 ns ]]> Example 4 <![CDATA[70.25 ** ]]> Comparative Example 4 <![CDATA[-2.15 ns ]]> Example 5 <![CDATA[75.37 ** ]]> Comparative Example 5 <![CDATA[-6.98 ns ]]> Example 6 <![CDATA[65.78 ** ]]> Comparative Example 6 <![CDATA[8.17 ns ]]> Example 7 <![CDATA[60.46 ** ]]> Comparative Example 7 <![CDATA[9.26 ns ]]> Example 8 <![CDATA[58.24 ** ]]> Comparative Example 8 <![CDATA[11.14 ns ]]> Example 9 <![CDATA[55.11 ** ]]> Comparative Example 9 <![CDATA[5.45 ns ]]> Example 10 <![CDATA[54.70 ** ]]> Embodiment 11 <![CDATA[78.35 ** ]]>

[0132] Note: When using the t-test method for statistical analysis, the significance is expressed as * indicates that P-value<0.05 indicates that * , P-value<0.01 is indicated as ** , P-value<0.001 is indicated as *** , P-value>0.05 is indicated as ns ;

[0133] As can be seen from Table 4, the implementation scheme of the present invention can effectively improve the skin damage caused by cortisol, promote skin repair and healing, and increase the resistance to cortisol stimulation. Among them, the scheme of Example 1 has the best effect, and the promotion rate of skin repair is 115.23%, which has a significant effect compared with the model group. Figure 2 It can be seen that after the zebrafish tail fin was cut, the zebrafish in the model control group could hardly recover normally, but when the scheme of Example 1 was applied, it could significantly resist the damage of cortisol, restore the skin repair ability, and promote the growth of the tail fin (the double-headed arrow area is the new tail fin of zebrafish); In addition, the experiment also found that the average length of the tail fin (203.10 pixels) of the composition of Example 1 was 2.67% higher than the average length of the tail fin (197.81 pixels) of the blank control group. From this data, it can also be seen that the composition prepared by Example 1 can offset the damage of cortisol and play a significant role in promoting the repair of the skin. However, when the active ingredient combination scheme was changed in Comparative Examples 1-9, the corresponding effects obtained were significantly reduced, and there was no repair effect on the skin. Even Comparative Examples 1-5 increased the damage of cortisol to the skin, and the promotion rate was <0%, which did not play a positive role in preventing, maintaining and defending damaged skin.

[0134] Effect Example 3

[0135] The effect examples of the present invention verify the efficacy of application examples 1-12, comparative application examples 1-10 and blank application examples applied to human body, specifically including the following methods:

[0136] According to the Technical Specifications for Safety of Cosmetics (2015), 176 subjects with sensitive skin aged 18-60 years (lactic acid stinging score > 3) were selected for the test. Under normal circumstances, the subjects underwent a randomized, half-face test, with 8 people in each group, and used the product for 28 consecutive days. Instrumental testing and clinical evaluation of skin indicators were performed on the 3rd, 7th, 14th and 28th days.

[0137] 1. The specific steps of instrument measurement are as follows:

[0138] After cleansing and moisturizing every morning and evening, the subjects took 1 ml of the product lotion and applied it to one side of the face, and massaged until absorbed. The other side of the face used a blank application example lotion (without the composition), and used it once in the morning and evening. On the day of the visit, the subjects washed their faces with clean water without applying any products, and sat quietly in an air-conditioned room with a temperature of 21±1℃ and a humidity of 50±10% for 20 minutes. The skin condition was quantified and photographed using instruments, including Tewameter TM Hex to measure TEWL, Corneometer CM825 to measure the MMV value of the skin stratum corneum moisture, and facial image analysis system VISIA-CR and image analysis software Image-Pro Plus7.0 IPP to analyze indicators such as skin red area ratio and picture comparison; data were recorded and the indicator improvement rate was calculated, indicator improvement rate = (value before use - value after use) / value before use × 100%, the data in Table 5 represents the improvement rate = (indicator improvement rate after use of the sample case - indicator improvement rate after use of the blank case) / indicator improvement rate after use of the blank case × 100%; the results are shown in Table 5;

[0139] Table 5

[0140]

[0141]

[0142]

[0143]

[0144]

[0145] Note: Compared with the blank application example, the improvement rate is significant, and P-value < 0.05 is indicated as * , P-value>0.05 is indicated as ns .

[0146] As can be seen from Table 5, when the technical solution provided by the present invention is adopted, the obtained emulsion has the excellent effects of increasing skin moisture, reducing transepidermal water loss, and reducing the proportion of red area. Specifically, at D3, the improvement rates of MMV, TEML and red area proportion indexes are above 62.18%, above 50.00%, and above 62.50%, respectively. At D14, the improvement rates of MMV, TEML and red area proportion indexes are above 51.63%, above 54.62%, and above 53.03%, respectively. At D28, the improvement rates of MMV, TEML and red area proportion indexes are above 60.63%, above 50.52%, and above 62.96%, respectively. All of them are significantly different from the blank application examples, and compared with the comparative application example 10 in which the purslane extract known to have a good effect of alleviating sensitivity is added, the present invention is also significantly improved;

[0147] When the compositions in comparative application examples 1-5 lack any one of the compositions of the present invention, or when other similar components are used to replace the components in the compositions in comparative application examples 6-9, no significant effects of reducing transepidermal water loss, increasing skin moisture content, and reducing the proportion of red area can be achieved;

[0148] In addition, pictures of the red area on the face before and after use of Application Example 1 are provided. Figure 3 As shown, from Figure 3 It can be clearly seen that the lotion provided by the present invention can significantly reduce the proportion of facial red area.

[0149] 2. Clinical evaluation includes the following steps:

[0150] Professional dermatologists graded the following objective symptoms (dryness, peeling, redness) according to the skin condition of the subjects at the test time (0th, 3rd, 7th, 14th, 28th day). The lower the score, the lighter it is, and the higher the score, the more severe it is. 0 means no symptoms, 1-3 means mild, 4-6 means moderate, and 7-9 means severe.

[0151] Clinical evaluation improvement rate = (value before use - value after use) / value before use × 100%; the data in Table 6 represent the improvement rate = (clinical evaluation improvement rate after use of the sample case - clinical evaluation improvement rate after use of the blank case) / clinical evaluation improvement rate after use of the blank case × 100%, and the results are shown in Table 6;

[0152] Table 6

[0153]

[0154]

[0155]

[0156]

[0157] Note: Compared with the blank application example, the improvement rate is significant, and P-value < 0.05 is indicated as * , P-value>0.05 is indicated as ns .

[0158] As can be seen from Table 6, when the technical solution provided by the present invention is adopted, the obtained emulsion also clinically shows excellent effects of relieving dryness, peeling and redness. Specifically, at D3, the clinical evaluation improvement rates of dryness, peeling and redness are above 90.00%, above 115.09%, and above 56.97%, respectively; at D14, the clinical evaluation improvement rates of dryness, peeling and redness are above 120.08%, above 101.89%, and above 64.42%, respectively; at D28, the clinical evaluation improvement rates of dryness, peeling and redness are above 244.93%, above 111.32%, and above 100.00%, respectively; compared with comparative application example 10 in which a purslane extract known to have a good effect of alleviating sensitivity is added, the present invention has also been significantly improved;

[0159] When the compositions in comparative application examples 1-5 lack any one of the compositions of the present invention, or when other similar components are used to replace the components in the compositions in comparative application examples 6-9, no significant effect of alleviating dryness, peeling and redness can be achieved.

[0160] 3. Scoring the usage effect

[0161] Since the human test shows that the lotion of Application Example 1 has the best effect, the use experience of 100 subjects corresponding to the lotion of Application Example 1 was collected, specifically, the subjects evaluated their satisfaction with the skin condition after use, and the product satisfaction percentage = the number of people who chose "satisfied" / the total number of testers × 100%. The results are shown in Table 7;

[0162] Table 7

[0163]

[0164] As can be seen from Table 7, in human body tests, the product provided by Application Example 1 of the present invention not only objectively improves sensitive symptoms with excellent effects, but also has high subjective scores and high scores in volunteer satisfaction.

[0165] Effect Example 4

[0166] The emulsions prepared by using Examples 1-12, Comparative Application Examples 1-10 and Blank Application Examples of the present invention were subjected to Evalwise AI emotion evaluation, i.e., the effects of different sample groups on human emotions were analyzed by micro-expression. The experiment was carried out for 14 days, and measurements were performed on the 0th, 7th and 14th days. The test method includes the following steps:

[0167] 9 subjects with sensitive skin (lactic acid stinging score>3) were recruited and divided into 3 groups. Each group corresponded to an imaging device with Evalwise AI software installed for testing. Each person in each group corresponded to 23 groups of samples, including use cases 1-12, comparison application cases 1-10 and blank application cases, and the original data was obtained for analysis. Before starting the test, the subject sat quietly in a quiet environment for 5 minutes to achieve emotional stability. The test software was turned on. The subject faced the camera without any obstruction, first sniffed the blank application case for 5 seconds, and then evenly applied it to the face, which was used as an emotional baseline. Then, the sample group lotion was sniffed 3 times, each time for 3-5 seconds, and evenly applied to the face. After staying for 1-3 minutes, AI captured the volunteer's facial micro-expressions within 30 seconds. Each experiment was repeated twice to take the average value, and four emotional information of pleasure, immersion, curiosity, and negative emotions were obtained, and converted into corresponding emotional intensity (the emotional baseline was set to 1); the results are analyzed as follows:

[0168] (1) Data identification and benchmarking: The video facial expression recognition system is used to identify the emotions of the interviewees during the anchoring phase (calibration phase in this project) and use them as the baseline emotions. At the same time, the emotional curve during the evaluation process is identified and compared with the emotional baseline value during the anchoring phase to obtain data that eliminates individual differences and is comparable.

[0169] (2) Determine the emotional effect area: According to the trend of time series data and the deviation from the baseline value, determine the emotional effect threshold (weakening interval, no significant change interval, and enhancement interval), and calculate the emotional value distribution of each frame in the corresponding emotional effect area;

[0170] (3) Emotion enhancement effect: If a certain emotion falls into the emotion enhancement range after the anchoring stage during the evaluation phase, it means that there is an emotion enhancement effect of a certain emotion in the evaluation process, including three indicators: emotion enhancement ratio, emotion enhancement intensity index, and emotion enhancement duration (emotion enhancement ratio: the ratio of people with a certain emotion enhancement; emotion enhancement intensity index: the indexed result of the emotion intensity of a certain emotion in the enhancement effect range and the comparison between the emotion and the anchoring stage; emotion enhancement duration: the duration of a certain emotion in the enhancement effect range, and the total duration of each evaluation period is set to 1);

[0171] In the actual experiment, it was found that the 0th, 7th and 14th days had similar trends, so the measurement data of the 14th day were displayed; the results obtained are shown in Tables 8-11 respectively;

[0172] Table 8

[0173]

[0174]

[0175] Table 9

[0176]

[0177]

[0178] Table 10

[0179]

[0180]

[0181] Table 11

[0182]

[0183]

[0184]

[0185] As can be seen from Tables 8-10, different application examples have different effects on the emotions of the subjects. Application examples 1-12 using the technical solution of the present invention have a significant enhancement effect on the human body's pleasant emotions, immersive emotions, and curious emotions. Among them, the best comprehensive one is application example 1, and the application effect is better than application examples 2-12, and there is a significant difference in the effect of the comparative application examples. Application example 1 can effectively and stably improve the human body's pleasure level, prolong the pleasure time, reduce negative emotions, and produce positive subjective reactions. In addition, from the results of Table 11, it can be seen that application example 1 has the highest proportion of ABC people with higher pleasure emotions, indicating that the product is relatively popular.

[0186] Finally, it should be noted that the above embodiments are intended to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for improving skin sensitivity and enhancing pleasant mood, characterized in that: The composition comprises the following components in parts by weight: 0.5-10 parts of Camellia chrysantha extract, 0.1-8 parts of Cnidium monnieri extract, 0.01-2 parts of 4-tert-butyl cyclohexanol, 0.005-1 parts of metallothionein, and 0.03-3 parts of Rehmannia glutinosa extract.

2. The composition according to claim 1, characterized in that The composition comprises the following components in parts by weight: 0.8-5 parts of Camellia chrysantha extract, 1-5 parts of Cnidium monnieri extract, 0.1-1.5 parts of 4-tert-butyl cyclohexanol, 0.008-0.1 parts of metallothionein, and 0.05-0.5 parts of Rehmannia glutinosa extract.

3. The composition according to claim 2, characterized in that The composition comprises the following components in parts by weight: 1 part of Camellia chrysantha extract, 3 parts of Cnidium monnieri extract, 1 part of 4-tert-butyl cyclohexanol, 0.01 parts of metallothionein, and 0.1 parts of Rehmannia glutinosa extract.

4. The composition according to claim 1, characterized in that The mass ratio of the Rehmannia root extract, 4-tert-butyl cyclohexanol and Camellia chrysantha extract is 1:(3-12):(6-20).

5. The composition according to claim 1, characterized in that The preparation method of the camellia chrysantha extract comprises the following steps: extracting camellia chrysantha powder by mixing it with an ethanol aqueous solution, and then concentrating the extract and drying it to obtain the camellia chrysantha extract.

6. The composition according to claim 5, characterized in that The preparation method of the golden camellia extract comprises the following steps: mixing golden camellia powder with ethanol aqueous solution, then extracting at 55-65° C. for 25-35 minutes, then ultrasonically extracting at 55-65° C. for 55-65 minutes, then concentrating the extract and drying to obtain the golden camellia extract; In the ethanol aqueous solution, the volume percentage of ethanol is 60-80%; the weight ratio of the golden camellia powder to the ethanol aqueous solution is 1:(5-10).

7. The composition according to claim 1, characterized in that The preparation method of the Cnidium monnieri extract comprises the following steps: extracting Cnidium monnieri powder by mixing with ethanol aqueous solution, and then concentrating, decolorizing and drying to obtain the Cnidium monnieri extract.

8. The composition according to claim 7, characterized in that The preparation method of the Cnidium monnieri extract comprises the following steps: taking Cnidium monnieri powder and mixing it with an ethanol aqueous solution added with a surfactant, refluxing and ultrasonically extracting it, and then concentrating, decolorizing and drying it to obtain the Cnidium monnieri extract.

9. The composition according to claim 8, characterized in that Contains at least one of the following (a)-(e): (a) the volume percentage of ethanol in the ethanol aqueous solution is 80-95%; (b) the weight ratio of the Cnidium monnieri powder to the ethanol aqueous solution is 1:(1-5); (c) based on the mass of the Cnidium monnieri powder, the amount of surfactant added is 0.01-0.4%; (d) the surfactant comprises at least one of Tween 20, Tween 60, Tween 80 and sodium lauryl sulfate; (e) The power of the ultrasound is 250-280W.

10. The composition according to claim 1, characterized in that The preparation method of the Rehmannia root extract comprises the following steps: taking Rehmannia root powder and subjecting it to supercritical carbon dioxide extraction, and then filtering and concentrating the extract to obtain the Rehmannia root extract.

11. Use of the composition according to any one of claims 1 to 10 in the preparation of cosmetics.

12. A cosmetic, characterized in that: The cosmetic comprises the composition according to any one of claims 1 to 10.

13. The cosmetic according to claim 12, characterized in that: The cosmetic comprises the following components in percentage by mass: 1-5% of the composition according to any one of claims 1 to 10, 4-40% of a cosmetic base, and the balance being water.

14. The cosmetic according to claim 13, characterized in that The cosmetic matrix includes at least one of a thickener, a moisturizer, an emulsifier, a preservative, and a pH adjuster.